The global next-generation biologics market is estimated to have reached $3.2bn in 2018. The market is expected to grow at a CAGR of 19.8% in the first half of the forecast period.

How this report will benefit you
  • Read on to discover how you can exploit the future business opportunities emerging in this sector.
  • In this brand new 296-page report you will receive 181 charts– all unavailable elsewhere.
  • The 296-page report provides clear detailed insight into the next-generation biologics market. Discover the key drivers and challenges affecting the market.
  • By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Next-Generation Biologics Market forecast to 2029
  • Revenue forecasts for the Next-Generation Biologics Market by Sector to 2029:
  • Regenerative Medicine: Stem Cell Therapies, Tissue Engineering, Gene Therapies
  • Next-Generation Antibody Therapies: ADC, Engineered Antibodies, Bispecific Antibodies
  • Next-Generation Antibody Fragments & ALPs
  • Next-Generation Insulin: Oral Insulin, Ultra- Rapid Acting Insulin, Ultra-Long Acting Insulin
  • Next-Generation Growth Hormones
  • Next-Generation Coagulating Factors
  • Others

Next-Generation Biologics Market Forecast to 2029

Revenue forecasts for the Next-Generation Biologics Market Forecast by Region to 2029:

North America:
  • U.S.
  • Canada
  • Germany
  • UK
  • France
  • Italy
  • Spain

  • Japan
  • China
  • India

  • Brazil
  • Mexico
  • Russia
  • South Africa

Profiles of the selected leading companies:
  • AbbVie
  • Amgen
  • Eli Lilly
  • GSK
  • Novo Nordisk
  • Roche/ Genentech
  • Sanofi Aventis
  • Seattle Genetics

The report also includes a STEP Analysis of the Next-Generation Biologics market.

Key questions answered by this report:
  • How is the next-generation biologics therapies market evolving?
  • What is driving and restraining the next-generation biologics market?
  • What are the market shares of segments of the overall next-generation biologics market in 2018?
  • How will each next-generation biologics segment grow over the forecast period and how much revenue will these submarkets account for by 2029?
  • How will the market shares for next-generation biologics therapies submarkets develop to 2029?
  • Which therapies can succeed and what are their revenue potentials?
  • What will be the main sales drivers for the overall market to 2029?
  • How will political and regulatory factors influence the regional markets and other submarkets?
  • How will the market shares of the regional markets change by 2029 and which geographical region will lead the market by 2029?
  • How will the industry evolve during the period between 2019 and 2029?